반응식
[NH:1]1[C:9]2[C:4](=[CH:5][CH:6]=[C:7]([NH:10][C:11]3[C:12]4[CH:30]=[CH:29][N:28](S(C5C=CC(C)=CC=5)(=O)=O)[C:13]=4[N:14]=[C:15]([NH:17][C:18]4[CH:23]=[CH:22][C:21]([S:24]([NH2:27])(=[O:26])=[O:25])=[CH:20][CH:19]=4)[N:16]=3)[CH:8]=2)[CH:3]=[N:2]1.[OH-].[K+]>O1CCOCC1>[NH:1]1[C:9]2[C:4](=[CH:5][CH:6]=[C:7]([NH:10][C:11]3[C:12]4[CH:30]=[CH:29][NH:28][C:13]=4[N:14]=[C:15]([NH:17][C:18]4[CH:19]=[CH:20][C:21]([S:24]([NH2:27])(=[O:26])=[O:25])=[CH:22][CH:23]=4)[N:16]=3)[CH:8]=2)[CH:3]=[N:2]1참가 물질
4
반응 조건
- 온도
- 70 °C
실험 절차
To a solution of 4-(4-(1H-indazol-6-ylamino)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzenesulfonamide (105 mg, 0.18 mmol) in dioxane (5 mL), aq. 1N KOH (1.50 mL, 1.50 mmol) was added. The mixture was then heated at 70° C. for 4 h. before it was concentrated in vacuo. The residue was then acidified with acetic acid (HOAc) (2.0 mL) and purified by HPLC to give the title compound (15 mg). MS 421.1 (M+H) (Compound 11-1).
후처리
- concentrationwas concentrated in vacuo
- custompurified by HPLC
출처 및 근거
- ORD 기록
- ord-4b20c94309334e139ad62b600d16009e
- 출처 데이터셋
- uspto-grants-2010_04
- 특허 번호
- US07705004B2
연결된 노트
불러오는 중…